Minimally Invasive Keratoprosthesis
微创人工角膜
基本信息
- 批准号:9386600
- 负责人:
- 金额:$ 22.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccidentsAllogenicAnimal ModelAnimalsAnteriorApplications GrantsAreaBackBasic ScienceBlindnessBlood VesselsBostonBurr hole procedureCellsClinicalClinical TrialsComputer-Aided DesignCorneaCytokeratinDevelopmentDevicesDiagnosisDiseaseDrainage procedureEarEngineeringEnvironmentEpithelialEyeEye InfectionsEye diseasesFacultyFailureFellowshipFlow CytometryFunctional disorderFundingGeneticGlaucomaGoalsHistologicHumanIllinoisImmuneImplantIndustrializationInfectionInflammationInstitutesInterleukin-1 betaInternshipsInvestigationKeratoplastyKnowledgeLightMeasuresMedicalMedical ResearchMembraneMoldsMonitorMyofibroblastNerve DegenerationOperative Surgical ProceduresOphthalmologistOptic NerveOpticsOryctolagus cuniculusPathologyPatientsPerforationPolymer ChemistryPolymersPolymethyl MethacrylatePrintingProcessProductionResearchResearch PersonnelResearch Project GrantsRetinalRetinal DiseasesRiskSECTM1 geneScientistStaining methodStainsStem cellsSurgeonSurgical suturesTNF geneTechniquesTechnologyTestingThickTimeTissue DonorsTissuesTitaniumTrainingTranslatingTranslational ResearchTransplantationUnited States National Institutes of HealthUniversitiesVisionVision researchWound Healingarmblindcareercombatdesignflexibilitygenome wide association studyhigh riskimplantationin vivoinjuredinnovationinstrumentinterestlight scatteringmaterials sciencememberminimally invasivenerve supplynew technologypressureprofessorprogramsprosthetic membraneprototyperestorationskillssquare footstemsuccesswound
项目摘要
Project Abstract
The objective of this grant application is to train Dr. Charles Yu in the scientific skills and knowledge necessary
for a career as an independent scientist translating scientific discoveries to clinically useful applications,
specifically the restoration of vision in patients with corneal blindness. In additional to the primary goal of
training Dr. Yu to become an independent investigator, this program may have a significant impact on the
treatment of corneal blindness through the development of a new corneal replacement technology.
Candidate
Dr. Yu is a fellowship trained ophthalmologist specializing in corneal blindness and has a deep interest in
developing new technologies to cure blindness. He is an expert in corneal innervation, developing artificial
corneas and animal models of eye disease, ocular infections, and refractive surgery clinical trials. He has a
strong background in the basic sciences having completed numerous research projects and a Howard Hughes
Medical Institute sponsored medical research fellowship. He is currently an assistant professor and a K12
scholar at the University of Illinois Eye and Ear Infirmary. During this training period he will take numerous
courses in engineering and materials science and complete two internships to develop his skill in polymer
chemistry and industrial design.
Environment
The University of Illinois Eye and Ear Infirmary is one of the largest centers of vision research in the US,
ranking top 4 in NIH funding in the last fiscal year. The department has a total of 47 full time faculty members,
with 24 of them engaged in basic science or translational research. The research program encompasses the
most critical areas of vision research, including investigations into the causes and pathology of blinding
diseases, the development of innovative techniques and instruments for diagnosing and monitoring the
progression of eye disease, genome-wide association studies of retinal diseases and visual functioning and
retinal processes. The department commits over 22,000 square feet of its physical space to research.
Research
The cornea comprises the outer anterior layer of the eye. A normal cornea is transparent and curved, focusing
light from the outside world. When injured by disease or dysfunction the cornea becomes opaque, causing
scattering of light and loss of visual function. In cases where corneal stem cells have been damaged or there is
vascularity, transplantation cannot be performed due to risk of rejection. Currently in these situations a Boston
Keratoprosthesis Type I (BKpro) can be performed. The 5 year success rate varies from 50-70% depending on
study.
However BKpro remains limited by its technical difficulty and rate of complications such as extrusion, infection,
and particularly membrane formation and glaucoma. These complications occur at a rate of up to 65% and
76%, respectively. There is a gap in the current understanding of why prosthetic membranes form and why
there is often relentless membrane formation or glaucoma in these patients despite placement of pressure
regulating glaucoma drainage devices. Also there is potential for design advances to reduce the complexity of
surgical implantation and need for donor cornea tissue. This study proposes the development of a easy to
implant minimally invasive keratoprosthesis (MiKpro) device, which can be implanted into the cornea through a
3 mm trephination without use of donor cornea tissue.
This study offers the opportunity to both study the pathophysiology leading to keratoprosthesis complications
and create a useful corneal replacement which can be implanted through a small wound and does not require
donor corneal tissue.
项目摘要
这项拨款申请的目的是训练余志强博士所需的科学技能和知识。
作为一名将科学发现转化为临床有用应用的独立科学家,
特别是角膜失明患者的视力恢复。除了以下主要目标之外
培养余博士成为独立调查员,这个项目可能会对
通过开发一种新的角膜置换技术治疗角膜失明。
侯选人
Yu博士是一位受过团契训练的眼科医生,专门研究角膜失明,并对
开发治疗失明的新技术。他是角膜神经支配方面的专家,研发人工角膜
眼部疾病、眼部感染和屈光手术的角膜和动物模型临床试验。他有一个
在基础科学方面有很强的背景,完成了许多研究项目,霍华德·休斯
医学研究所赞助了医学研究奖学金。他目前是一名助理教授和K12。
伊利诺伊大学眼耳医院的学者。在这段训练期间,他将接受许多
工程和材料科学课程,并完成两次实习以发展他在聚合物方面的技能
化学和工业设计。
环境
伊利诺伊大学眼耳医院是美国最大的视力研究中心之一,
在上一财年排名NIH资金前4名。该系共有47名全职教职员工,
其中24人从事基础科学或翻译研究。这项研究计划包括
视力研究的最关键领域,包括对致盲原因和病理的调查
疾病,开发诊断和监测疾病的创新技术和仪器
眼科疾病的进展,视网膜疾病和视觉功能的全基因组关联研究
视网膜突起。该部门承诺将超过22,000平方英尺的物理空间用于研究。
研究
角膜由眼睛的外前层组成。正常的角膜是透明的,弯曲的,聚焦的
来自外部世界的光。当因疾病或功能障碍而受伤时,角膜会变得浑浊,导致
光线散射和视觉功能丧失。在角膜干细胞受损或存在
由于有排斥反应的风险,不能进行血管移植。目前在这些情况下,一架波士顿
可以实施I型角膜假体(BKPRO)。5年成功率从50%到70%不等,具体取决于
学习。
然而,BKPro仍然受到其技术难度和挤出、感染、
尤其是膜形成和青光眼。这些并发症的发生率高达65%,
分别为76%。目前对人工膜形成的原因和原因的理解存在一个空白。
在这些患者中,尽管施加了压力,但通常会出现无情的膜形成或青光眼。
规范青光眼引流装置。此外,设计上的进步也有可能降低
手术植入并需要供体角膜组织。这项研究提出了一种易于开发的
植入性微创角膜假体(MiKpro)装置,可通过角膜植入
3 mm钻孔,不使用供体角膜组织。
这项研究为研究导致角膜假体并发症的病理生理学提供了机会
并创造出一种有用的角膜替代物,它可以通过一个小伤口植入,不需要
供体角膜组织。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Qian Yu其他文献
Charles Qian Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 22.62万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 22.62万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 22.62万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 22.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)